Evolent Health, Inc. (EVH) Stock Price & Analysis
Evolent Health, Inc. (EVH) rose 1.29% to USD 4.72 as of June 10, 2026 at 05:26 UTC, according to Nexqual real-time market data.
EVH last closed at USD 4.66; the session ranged USD 4.55–4.84 on volume of 2,957,282 shares. Market capitalization is $530.91M, with a 52-week range of USD 2.1–12.07 (NYQ). Source: Nexqual, June 10, 2026 at 05:26 UTC.
Key Statistics (as of June 10, 2026 at 05:26 UTC)
| Price | USD 4.72 |
|---|---|
| Change | ▲ 1.29% (up) |
| Previous Close | USD 4.66 |
| Open | USD 4.58 |
| Day Range | USD 4.55 – 4.84 |
| 52-Week Range | USD 2.1 – 12.07 |
| Volume | 2,957,282 shares |
| Market Cap | $530.91M |
| Exchange | NYQ |
Technical Analysis (EVH)
Nexqual's technical model rates EVH "BUY" based on 5 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 05:26 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 66.87 (neutral) |
| vs SMA50 | Above (USD 3.42) |
| MACD | 0.2 (positive) |
Analyst Ratings (EVH)
Wall Street analysts rate EVH "None" based on 14 analysts, with a mean price target of USD 5.75 (range USD 3–8), per Nexqual as of June 10, 2026 at 05:26 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 5.75 |
| High Target | USD 8 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 14 / 2 / 0 |
Earnings (EVH)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.02 |
| Revenue Estimate | $599.07M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.02 vs est -0.05 ▲ beat |
| 2025-12-31 | USD 0.08 vs est 0.05 ▲ beat |
| 2025-09-30 | USD 0.05 vs est 0.1 ▼ miss |
| 2025-06-30 | USD -0.1 vs est 0.08 ▼ miss |
Source: Nexqual, June 10, 2026 at 05:26 UTC.
Financials & Fundamentals (EVH)
| Total Revenue | $1.89B |
|---|---|
| Revenue Growth (YoY) | +2.60% |
| Gross Margin | +20.18% |
| Operating Margin | -2.04% |
| Profit Margin | -26.29% |
| ROE | -65.11% |
| Debt / Equity | 248.6 |
| Current Ratio | 1.32 |
| Total Cash | $142.03M |
| Total Debt | $985.43M |
| Free Cash Flow | $52.93M |
Source: Nexqual, June 10, 2026 at 05:26 UTC.
Financial Health Score (EVH)
Nexqual rates Evolent Health, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:26 UTC.
| Growth | Critical — Revenue -27% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Gross margin 20%, operating -2% |
| Balance Sheet | Weak — $142M cash vs $985M debt |
| Cash Flow | Mixed — FCF $53M, slim 2.8% margin |
| Efficiency | Critical — ROE -65%, ROA -0.4% |
Ownership (EVH)
| Insider Ownership | +2.16% |
|---|---|
| Institutional Ownership | +100.95% |
| Shares Outstanding | 112.48M |
| Float | 94.22M |
| Short % of Float | +13.30% |
Source: Nexqual, June 10, 2026 at 05:26 UTC.
Leadership (EVH)
Evolent Health, Inc. is led by Seth Barrie Blackley (age 46), Co-Founder, CEO & Director, per Nexqual as of June 10, 2026 at 05:26 UTC.
| Co-Founder, CEO & Director | Seth Barrie Blackley (age 46) |
|---|---|
| President | Dan McCarthy (age 40) |
| Chief Strategy Officer | John Paul Johnson (age 41) |
| Chief Financial Officer | Mario Marques Ramos (age 53) |
| Chief Operating Officer | Katie DiPerna Cook |
Major Backers & Investors (EVH)
Notable institutional backers of Evolent Health, Inc. include Cadian Capital Management, LP, Morgan Stanley, UBS Group AG, according to Nexqual as of June 10, 2026 at 05:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Cadian Capital Management, LP | 9.61% |
| Morgan Stanley | 8.07% |
| UBS Group AG | 7.25% |
| Rubicon Founders LLC | 5.17% |
| Engaged Capital, LLC | 4.95% |
| Shaw D.E. & Co., Inc. | 4.83% |
| Rock Springs Capital Management, LP | 2.38% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.63% |
| Vanguard Group | 9.08% |
| State Street | 2.35% |
Source: Nexqual, June 10, 2026 at 05:26 UTC.
From Evolent Health, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States.
- The company offers integrated value-based care platform for health plan administration and management.
- It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.
- In addition, the company provides Machinify Auth Intelligence, an artificial intelligence tool to aid nurses and physicians in completing clinical review of prior authorization requests.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SGRY | Surgery Partners, Inc. | USD 13.96 | ▲ 1.82% |
| PRVA | Privia Health Group, Inc. | USD 22.17 | ▲ 2.5% |
| GKOS | Glaukos Corporation | USD 126.34 | ▲ 1.07% |
| ITGR | Integer Holdings Corporation | USD 94.1 | ▲ 2.3% |
| PHR | Phreesia, Inc. | USD 9.29 | ▼ 2.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:26 UTC. This page is informational and not investment advice.